

Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting  
**February 12, 2019**

The ODM DUR Board meeting was called to order at 12:00 PM EST in room C621  
50 West Town Street, Columbus, Ohio. A. Mehran Mostafavifar, M.D. presided.

The following Board members were present:

Michelle Barger, Pharm.D.  
David Brookover, R.Ph.  
Michael Dietz, D.O., Co-Chair  
A. Mehran Mostafavifar, M.D., Chair  
Lenard Presutti, D.O.  
Stacey Rexrode Brewer Pharm.D.  
Donald Sullivan, Ph.D., R.Ph.

Also present from ODM were Tracey Archibald, Pharm.D. and Scott Baran, R.Ph. Change Healthcare attendees included Jill R.K. Griffith, BS, Pharm.D., Benjamin Link, Pharm.D. and Gail Master, R.Ph. Approximately 12 observers were present, mostly representing pharmaceutical manufacturers.

Roll Call, Reading, Correction, and Approval of Previous Minutes

The November 13, 2018 DUR Board Meeting Minutes were approved.

OUR Committee Report

G. Master presented a summary of the RetroDUR intervention directed at the prescribers of members taking concurrent opioids, benzodiazepines, and sedative hypnotics.

G. Master presented the re-review results of the high dose and duplicate proton pump inhibitor (PPI) intervention.

G. Master presented the re-review results of the HIV medication adherence intervention. There were 16 members who were no longer taking HIV medications and calls were made to prescribers to follow up.

S. Baran shared the conversation he had with an appreciative prescriber regarding the HIV medication adherence intervention. Discussion focused on a re-review of this intervention in the future which would include these members who were no longer taking HIV medications.

Health Plan Policy

M. Barger presented the Health Plan Policy. She announced that the Ohio Department of Medicaid has a new Director, Director Maureen Corcoran.

She welcomed a new DUR Board member, Stacey Rexrode-Brewer. S. Rexrode-Brewer is a pharmacist who previously served on the ODM DUR Committee.

She announced that there is a new member on the Pharmacy & Therapeutics Committee, Dr. Nathan Samsa.

Next, she announced that the Unified Preferred Drug List had been delayed indefinitely. This delay did not impact the planned changes to Medication Assisted Treatment for Opioid Addiction, or the Hepatitis C clinical criteria discussed at the previous meeting.

She announced that a new Coordinated Service Program (CSP) rule went into effect on January 1<sup>st</sup> 2019. This rule applies to both Managed Care Plans and Fee-For-Service.

Lastly, she announced that this year the Centers for Medicare and Medicaid Services (CMS) Annual DUR

report will include Managed Care Plan DUR program information. The Board will be updated on the status of this report during future meetings.

#### Unfinished Business

There was no unfinished business.

#### New Business

G. Master provided an overview of the January 2019 Diabetes medication adherence intervention which was directed at prescribers whose patients had an adherence rate of 60 percent or below for antidiabetic medications. The Board reviewed the prescriber letter.

G. Master then reviewed the new CSP criteria that was initiated on January 1, 2019.

Next, G. Master reviewed the planned 2019 calendar of RetroDUR interventions. The Board recommended that the March intervention focus on members who are using insulin without glucose test strips. The Board recommended that the December intervention focus on members who are taking opioids in conjunction with a benzodiazepine and a stimulant.

The October naloxone prescription intervention was discussed. The goal of the intervention was also discussed. D. Sullivan suggested an addictionologist review the content of the letter. The Board referenced the new opioid prescribing for chronic pain rules. The draft letter will be brought to the DUR Board in September for review.

G. Master presented the DUR Digest and D. Sullivan suggested that next DUR Digest issue contain an update regarding the subacute pain prescribing guidelines for opioids. He also suggested that the new Ohio Automated RX Reporting System (OARRS) tracking of naltrexone and medical marijuana be added.

#### Announcements

The dates for the next DUR Board meetings were set as follows:

- May 14, 2019
- September 17, 2019
- November 12, 2019

#### Adjournment

Dr. Mostafavifar adjourned the meeting at 12:42 P.M.